Bisphenol A and Muscle Insulin Sensitivity
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Neurology, Endocrine, Endocrine |
| Therapuetic Areas: | Endocrinology, Neurology |
| Healthy: | No |
| Age Range: | 18 - 50 |
| Updated: | 2/27/2019 |
| Start Date: | January 1, 2019 |
| End Date: | December 31, 2021 |
Randomized Trial Examining Oral Consumption of Bisphenol A on Type 2 Diabetes Risk Markers
This study examine oral bisphenol A consumption on muscle insulin sensitivity and hepatic
glucose suppression. Half of the participants will receive a diet plus BPA and the other half
will receive a diet plus no bisphenol A.
glucose suppression. Half of the participants will receive a diet plus BPA and the other half
will receive a diet plus no bisphenol A.
Evidence linking bisphenol A exposure with diabetes risk remains mainly associative in
nature, and mechanism linking bisphenol A to type 2 diabetes remains unclear. The
investigator's preliminary data suggests that in young adults, single oral BPA consumption
significantly decreased glucose, insulin, and C-Peptide responses to an oral glucose
tolerance test, suggesting that immediate consumption of bisphenol A has an effect on muscle
insulin sensitivity, hepatic glucose suppression and/or digestion and absorption to lower
blood glucose, insulin, and C-Peptide concentrations. The present experimental study
evaluating the effects of bisphenol A over several days on the pathogenesis of type 2
diabetes will directly assess each of these potential mechanisms using gold standard measures
(euglycemic hyperinsulinemic clamp technique and hepatic glucose suppression with glucose
stable isotope infusion, and fecal microbiota).
nature, and mechanism linking bisphenol A to type 2 diabetes remains unclear. The
investigator's preliminary data suggests that in young adults, single oral BPA consumption
significantly decreased glucose, insulin, and C-Peptide responses to an oral glucose
tolerance test, suggesting that immediate consumption of bisphenol A has an effect on muscle
insulin sensitivity, hepatic glucose suppression and/or digestion and absorption to lower
blood glucose, insulin, and C-Peptide concentrations. The present experimental study
evaluating the effects of bisphenol A over several days on the pathogenesis of type 2
diabetes will directly assess each of these potential mechanisms using gold standard measures
(euglycemic hyperinsulinemic clamp technique and hepatic glucose suppression with glucose
stable isotope infusion, and fecal microbiota).
Inclusion Criteria:
- non-dieting
- sedentary (<1 hour/week of aerobic exercise)
- normal-weight (BMI = 18.5 to 24.9 kg/m2)
- weight-stable for the previous 6 months
- free of any metabolic or chronic disease
- non-smoking, and sedentary
Exclusion Criteria:
- Hemoglobin A1C based on the American Diabetes Association guidelines of 5.7 to 6.4%
(Prediabetes) or >6.4% (Diabetes)
- impaired glucose tolerance
- type 1 diabetes
- type 2 diabetes
- colitis or any inflammatory bowel condition
- neurologic or psychiatric conditions
- smoking
- special diets (e.g. vegetarian, low-carbohydrate, Paleolithic, etc.)
- pregnant women or women trying to become pregnant
- women on oral contraceptives will be excluded.
We found this trial at
1
site
Click here to add this to my saved trials
